On demand presentation
Recent advancements in patient-derived organoid technology and their impact on drug developmentDr. Sylvia F. Boj, Chief Scientific Officer
The recent approval of the FDA Modernization Act 2.0 has registered a shift towards alternative in vitro models for drug discovery and development. Patient-derived organoids represent a new frontier in drug development as they can be developed from both normal and disease tissue to test the efficacy and toxicity of new drugs and most importantly, remain stable when expanded ex vivo in the lab, which makes them an invaluable tool for drug screening.
PDOs offer a powerful tool for developing and validating drugs, supporting the screening of the efficacy of both small and big molecules, and reducing the time and cost required to develop compounds that increase patient benefits. The feasibility of reducing and replacing animal models in drug development has been demonstrated by a recent paper published in Nature Cancer, where colorectal cancer (CRC) PDOs were used to identify a lead bispecific antibody that reached clinical trials within 5 years from the initial development. Organoid Technology is exponentially growing, with the innovation of novel assays that extends the utility of the PDO screening platform as clinically relevant preclinical models in immuno-oncology, inflammatory diseases, infectious diseases, and toxicology.
During the webinar, we will present the most recent scientific breakthroughs that have contributed to the growth of patient-derived organoid technology. This will include our progress in developing an organoid-based immuno-oncology co-culture platform, which can be used to evaluate the potency and toxicity of new immunotherapeutics. In addition, we will discuss our latest enhancements in the organoid biobank, as well as our progress in creating innovative assays and readouts.